![R. Mark Payne](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Posizioni attive di R. Mark Payne
Società | Posizione | Inizio | Fine |
---|---|---|---|
Chondrial Therapeutics, Inc.
![]() Chondrial Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Chondrial Therapeutics, Inc. operates as a biotechnology company which focuses on the treatment of rare mitochondrial diseases. Its compound is CTI-1601, which the company is developing as a potential treatment for Friedreich’s Ataxia. The company was founded by Steven R. Plump and Mark R. Payne and is headquartered in Bala Cynwyd, PA. | Direttore/Membro del Consiglio | - | - |
Direttore Tecnico/Scientifico/R&S | - | - | |
Fondatore | - | - |
Storia della carriera di R. Mark Payne
Statistiche
Distribuzione geografica
Stati Uniti | 2 |
Posizioni
Director/Board Member | 1 |
Chief Tech/Sci/R&D Officer | 1 |
Founder | 1 |
Settori
Health Technology | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Aziende private | 1 |
---|---|
Chondrial Therapeutics, Inc.
![]() Chondrial Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Chondrial Therapeutics, Inc. operates as a biotechnology company which focuses on the treatment of rare mitochondrial diseases. Its compound is CTI-1601, which the company is developing as a potential treatment for Friedreich’s Ataxia. The company was founded by Steven R. Plump and Mark R. Payne and is headquartered in Bala Cynwyd, PA. | Health Technology |
- Borsa valori
- Insiders
- R. Mark Payne
- Esperienza